Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Septic shock: desperately seeking treatment.

Huet O, Chin-Dusting JP.

Clin Sci (Lond). 2014 Jan 1;126(1):31-9. doi: 10.1042/CS20120668. Review. Erratum in: Clin Sci (Lond). 2014 Mar;126(6):459.

PMID:
24020445
2.

Novel potential therapies for septic shock.

Azevedo LC, Park M, Schettino GP.

Shock. 2008 Oct;30 Suppl 1:60-6. doi: 10.1097/SHK.0b013e318181a425. Review.

PMID:
18704007
3.

Possible therapies of septic shock: based on animal studies and clinical trials.

Wu CC.

Curr Pharm Des. 2006;12(27):3535-41. Review.

PMID:
17017946
4.

[Which therapeutic prospects in the septic syndrome?].

Leone M, Bourgoin A, Antonini F, Albanèse J, Martin C.

Ann Fr Anesth Reanim. 2003 Nov;22(9):798-808. Review. French.

PMID:
14612167
5.

Treatment of sepsis and septic shock: a review.

Wiessner WH, Casey LC, Zbilut JP.

Heart Lung. 1995 Sep-Oct;24(5):380-92; quiz 392-3. Review.

PMID:
8567303
6.

Endotoxin as a drug target.

Opal SM, Glück T.

Crit Care Med. 2003 Jan;31(1 Suppl):S57-64. Review.

PMID:
12544978
7.
8.

Is nitric oxide overproduction the target of choice for the management of septic shock?

Feihl F, Waeber B, Liaudet L.

Pharmacol Ther. 2001 Sep;91(3):179-213. Review.

PMID:
11744067
9.

Modern approaches to the therapy of septic shock.

Putterman C.

Am J Emerg Med. 1990 Mar;8(2):152-61. Review.

PMID:
2405867
10.

The rat in sepsis and endotoxic shock.

Wise WC, Cook JA, Tempel GE, Reines HD, Halushka PV.

Prog Clin Biol Res. 1989;299:243-52. Review.

PMID:
2657793
11.

Early biomarker activity in severe sepsis and septic shock and a contemporary review of immunotherapy trials: not a time to give up, but to give it earlier.

Rivers EP, Jaehne AK, Nguyen HB, Papamatheakis DG, Singer D, Yang JJ, Brown S, Klausner H.

Shock. 2013 Feb;39(2):127-37. doi: 10.1097/SHK.0b013e31827dafa7. Review.

PMID:
23324881
12.
13.

Possible interventional therapies in severe sepsis or septic shock.

Wu CC.

Acta Anaesthesiol Taiwan. 2012 Jun;50(2):74-7. doi: 10.1016/j.aat.2012.05.003. Epub 2012 Jun 19. Review.

14.

Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock.

Humes HD, Buffington DA, Lou L, Abrishami S, Wang M, Xia J, Fissell WH.

Crit Care Med. 2003 Oct;31(10):2421-8.

PMID:
14530746
15.

Hemodynamic and oxygen transport monitoring to titrate therapy in septic shock.

Shoemaker WC, Appel PL, Kram HB, Bishop M, Abraham E.

New Horiz. 1993 Feb;1(1):145-59. Review.

PMID:
7922388
16.

[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] .

Baudo F, de Cataldo F.

Minerva Anestesiol. 2000 Nov;66(11 Suppl 1):3-23. Review. Italian.

PMID:
11213542
17.

The use of immunocompromised animals as models for human septic shock.

Opal SM, Cross AS.

Shock. 2005 Dec;24 Suppl 1:64-70.

PMID:
16374375
18.

Septic shock: new pharmacotherapy options or better trial design?

Vincent JL, Van Nuffelen M.

Expert Opin Pharmacother. 2013 Apr;14(5):561-70. doi: 10.1517/14656566.2013.777429. Epub 2013 Mar 4. Review.

PMID:
23452102
19.

Endotoxin as a therapeutic target in septic shock.

Corriveau CC, Danner RL.

Infect Agents Dis. 1993 Feb;2(1):35-43. Review.

PMID:
8162352
20.

Mouse models of resuscitated shock.

Hollenberg SM.

Shock. 2005 Dec;24 Suppl 1:58-63. Review.

PMID:
16374374

Supplemental Content

Support Center